Stockscreener 앱 받기
1.90
5.47%
-0.11
시간 외 거래:
1.93
0.03
+1.58%
전일 마감가:
$2.01
열려 있는:
$1.99
하루 거래량:
1.69M
Relative Volume:
0.82
시가총액:
$88.50M
수익:
-
순이익/손실:
$-37.65M
주가수익비율:
-1.1377
EPS:
-1.67
순현금흐름:
$-24.14M
1주 성능:
+5.56%
1개월 성능:
+61.02%
6개월 성능:
+77.57%
1년 성능:
-63.84%
1일 변동 폭
$1.895
$2.045
1주일 범위
$1.63
$2.045
52주 변동 폭
$0.60
$5.67
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
명칭
Reviva Pharmaceuticals Holdings Inc
전화
(408) 501-8881
주소
10080 N WOLFE ROAD, CUPERTINO
RVPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVPH
Reviva Pharmaceuticals Holdings Inc
|
1.90 | 88.50M | 0 | -37.65M | -24.14M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-09-20 | 개시 | ROTH MKM | Buy |
| 2023-06-08 | 개시 | The Benchmark Company | Speculative Buy |
| 2022-01-24 | 개시 | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc 주식(RVPH)의 최신 뉴스
Reviva Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals to Participate in the UBS Global Healthcare Conference - Marketscreener.com
What is Zacks Small Cap’s Estimate for RVPH FY2024 Earnings? - Defense World
FY2024 Earnings Forecast for RVPH Issued By Zacks Small Cap - MarketBeat
RVPH: Preliminary OLE Readout - Yahoo Finance
Reviva Pharmaceuticals Strengthens Financial Position with Offering - Yahoo Finance
Reviva Pharmaceuticals Announces Positive Preliminary Data from RECOVER Trial – - Defense World
Reviva announces pricing of $18M public offering of common stock and warrants - MSN
Reviva Pharmaceuticals Shares Slide Premarket After Stock Offering - MarketWatch
CNS Drug-Maker Reviva Announces $18M Public Offering of Common Stock and Warrants to Fund R&D - geneonline
Reviva Pharmaceuticals Announces $18M Public Offering with Warrant Package to Fund R&D Pipeline - StockTitan
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants - GlobeNewswire
Reviva Announces Proposed Public Offering - GlobeNewswire
Reviva Pharmaceuticals Launches Public Offering to Fund CNS Drug Development Pipeline - StockTitan
Reviva Pharmaceuticals Reports Positive Phase 3 Trial Results - TipRanks
Reviva Announces Positive Preliminary Topline Data for the - GlobeNewswire
Reviva's Brilaroxazine Shows Promising Long-Term Results in Phase 3 Schizophrenia Trial - StockTitan
Reviva Pharmaceuticals Holdings, Inc. Holds Annual Meeting and Approves Increase in Authorized Shares - Defense World
Largest borrow rate increases among liquid names - TipRanks
Reviva Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low - Seeking Alpha
Analyzing Reviva Pharmaceuticals (NASDAQ:RVPH) and Akebia Therapeutics (NASDAQ:AKBA) - Defense World
RVPH: Year-End OLE Update - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires New Stake in Reviva Pharmaceuticals Holdings Inc - GuruFocus.com
Schonfeld Strategic Advisors LLC Increases Stake in Reviva Pharm - GuruFocus.com
Reviva Pharmaceuticals Holdings Inc. Warrants (RVPHW) Quarterly 10-Q Report - Quartzy
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Reviva Pharma: 108 Patients Complete 1-Year Schizophrenia Drug Trial as Losses Narrow | RVPH Stock News - StockTitan
Reviva reports progress in schizophrenia treatment study By Investing.com - Investing.com Australia
Reviva reports progress in schizophrenia treatment study - Investing.com
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - GlobeNewswire
Reviva's Brilaroxazine Hits Key Milestone: 108 Patients Complete 1-Year Schizophrenia Trial | RVPH Stock News - StockTitan
Reviva Pharmaceuticals Progresses with Brilaroxazine Study Update - TipRanks
Reviva to Present Positive Speech Latency Data for - GlobeNewswire
Reviva Pharma to Present Breakthrough Phase 3 Schizophrenia Drug Data at CNS Summit | RVPH Stock News - StockTitan
Reviva to Participate in the UBS Global Healthcare Conference - GlobeNewswire
Reviva To Report Long-Term Safety Data For Brilaroxazine In Schizophrenia: Will The Stock Recover? - RTTNews
Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight - GlobeNewswire Inc.
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst - Benzinga
Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewswire
Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion - Barchart
Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference - The Manila Times
CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment - Streetwise Reports
RVPH’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Market Momentum: Reviva Pharmaceuticals Holdings Inc. (RVPH) Registers a 9.40 Increase, Closing at 1.28 - The Dwinnex
RVPH: RECOVER Biomarker KOL Event - Yahoo Finance
Reviva Pharmaceuticals Holdings Inc (RVPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.60%
2.24%
자본화:
|
볼륨(24시간):